```

[Federal Register Volume 89, Number 239 (Thursday, December 12, 2024)]
[Notices]
[Pages 100507-100508]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-29231]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2024-N-0008]

Advisory Committee; Science Board to the Food and Drug 
Administration; Renewal

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; renewal of Federal advisory committee.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or the Agency) is 
announcing the renewal of the Science Board to the Food and Drug 
Administration by the Commissioner of Food and Drugs (the 
Commissioner). The Commissioner has determined that it is in the public 
interest to renew the Science Board to the Food and Drug Administration 
for an additional 2 years beyond the charter expiration date. The new 
charter will be in effect until the June 26, 2026, expiration date.

DATES: Authority for the Science Board to the Food and Drug 
Administration will expire on June 26, 2026, unless the Commissioner 
formally determines that renewal is in the public interest.

FOR FURTHER INFORMATION CONTACT: Rakesh Raghuwanshi, Office of the 
Chief Scientist, Office of the Commissioner, Food and Drug 
Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 3309, Silver 
Spring, MD 20993-0002, 301-796-4769, [email protected].

SUPPLEMENTARY INFORMATION: Pursuant to 41 CFR 102-3.65 and approval by 
the Department of Health and Human Services and by the General Services 
Administration, FDA is announcing the renewal of the Science Board to 
the Food and Drug Administration (the Committee). The Committee is a 
discretionary Federal advisory committee established to provide advice 
to the Commissioner. The Committee advises the Commissioner or designee 
in discharging responsibilities as they relate to helping to ensure 
safe and effective drugs for human use and, as required, any other 
product for which FDA has regulatory responsibility.
    The Committee shall provide advice to the Commissioner and other 
appropriate officials on specific complex scientific and technical 
issues important to FDA and its mission, including emerging issues 
within the scientific community. Additionally, the Committee will 
provide advice that supports the Agency in keeping pace with technical 
and scientific developments, including in regulatory science; and input 
into the Agency's research agenda and on upgrading its scientific and 
research facilities and training opportunities. It will also provide, 
where requested, expert review of Agency-sponsored intramural and 
extramural scientific research programs.
    The Committee shall consist of a core of 21 voting members 
including a Chair and Co-Chair. The members, Chair, and Co-Chair are 
selected by the Commissioner or designee from among authorities 
knowledgeable in the fields of food science, safety, and nutrition; 
chemistry; pharmacology; translational and clinical medicine and 
research; toxicology; biostatistics; medical devices; imaging; 
robotics; cell and tissue based products; regenerative medicine; public 
health and epidemiology; international health and regulation; product 
safety; product manufacturing sciences and quality; and other 
scientific areas relevant to FDA-regulated products such as systems

[[Page 100508]]

biology, informatics, nanotechnology, and combination products. Members 
will be invited to serve for overlapping terms of up to 4 years. Non-
Federal members of this committee will serve as Special Government 
Employees or representatives. Federal members will serve as Regular 
Government Employees or Ex-Officios. The core of voting members may 
include one technically qualified member, selected by the Commissioner 
or designee, who is identified with consumer interests and is 
recommended by either a consortium of consumer-oriented organizations 
or other interested persons.
    The Commissioner or designee shall have the authority to select 
members of other scientific and technical FDA advisory committees 
(normally not to exceed 10 members) to serve temporarily as voting 
members and to designate consultants to serve temporarily as voting 
members when: (1) expertise is required that is not available among 
current voting standing members of the Committee (when additional 
voting members are added to the Committee to provide needed expertise, 
a quorum will be based on the combined total of regular and added 
members), or (2) to comprise a quorum when, because of unforeseen 
circumstances, a quorum is or will be lacking. Because of the size of 
the Committee and the variety in the types of issues that it will 
consider, FDA may, in connection with a particular committee meeting, 
specify a quorum that is less than a majority of the current voting 
members. The Agency's regulations (21 CFR 14.22(d)) authorize a 
committee charter to specify quorum requirements.
    If functioning as a medical device panel, an additional non-voting 
representative member of consumer interests and an additional non-
voting representative member of industry interests will be included in 
addition to the voting members.
    Further information regarding the most recent charter and other 
information can be found at https://www.fda.gov/advisory-committees/committees-and-meeting-materials/science-board-food-and-drug-administration or by contacting the Designated Federal Officer (see FOR 
FURTHER INFORMATION CONTACT). In light of the fact that no change has 
been made to the committee name or description of duties, no amendment 
will be made to 21 CFR 14.100.
    This notice is issued under the Federal Advisory Committee Act as 
amended (5 U.S.C. 1001 et seq.). For general information related to FDA 
advisory committees, please visit us at https://www.fda.gov/AdvisoryCommittees/default.htm.

    Dated: December 4, 2024.
P. Ritu Nalubola,
Associate Commissioner for Policy.
[FR Doc. 2024-29231 Filed 12-11-24; 8:45 am]
BILLING CODE 4164-01-P
```